Sitagliptin improves vascular endothelial function in Japanese type 2 diabetes patients without cardiovascular disease

Abstract

We evaluated the effect of sitagliptin on vascular endothelial function in Japanese type 2 diabetes patients without cardiovascular disease. Subjects included 24 Japanese type 2 diabetes patients without cardiovascular disease. This study was a prospective, open-label, randomized clinical trial. We divided the study subjects into 2 groups: subjects who received sitagliptin 50 mg daily (sitagliptin group, n = 12) and subjects who did not receive sitagliptin (control group, n = 12). Brachial artery flow-mediated dilation (FMD) was measured after overnight fasting. Sitagliptin administration was initiated at 1 month after enrollment in study (baseline). FMD and level of biochemical variables in the sitagliptin and control groups were measured at baseline and 3 months from baseline (3 months). We evaluated the effect of sitagliptin on vascular endothelial function by measuring FMD. FMD at 3 months was significantly higher in the sitagliptin group than in the control group (5.36% ± 2.18% vs 3.41% ± 2.29%, P = 0.040), while FMD at baseline was not significantly different between the 2 groups. In addition, FMD of the sitagliptin group at 3 months was significantly higher than that at baseline (5.36% ± 2.18% vs 3.67% ± 2.30%, P = 0.004), while no significant differences were observed in the FMD of the control group during the study period. The change in the adiponectin from baseline to 3 months was significantly higher in the sitagliptin group than that in the control group (0.82 ± 2.18 μg/mL vs 0.01 ± 0.55 μg/mL, P = 0.039). Sitagliptin improves vascular endothelial function of the brachial artery in Japanese type 2 diabetes patients without cardiovascular disease. Furthermore, elevation of adiponectin may induce reduction of endothelial dysfunction in type 2 diabetes patients treated with sitagliptin

Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report

“…A clinical report showed that sitagliptin treatment for 3 months increases adiponectin levels in patients with diabetes mellitus [27]. This report also suggests that improvement of endothelial function by sitagliptin therapy is associated with the change in adiponectin.…”

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

“…It has been reported that 12-week treatment with sitagliptin (DPP-4 inhibitor) produced a mean ∆FMD of 1.69 ± 1.76% (±SD) [22]. Accordingly, we assumed that a similar ∆FMD would be expected after 16-week dapagliflozin therapy.…”

Vascular Protection with Dipeptidyl Peptidase-IV inhibitors in Diabetes: Experimental and Clinical Therapeutics

“…Gliptins also enhance NO production and promote NO bioactivity, which may in part contribute to improved vascular function. These beneficial vascular protective effects are thoroughly supported by up‐to‐date clinical and experimental evidence . Gliptin‐associated vascular protective effects may in part be direct, but are likely mediated by increases in vasoprotective DPP‐IV substrates, including both incretin and nonincretin molecules.…”

“…8,10,30,31 Clinical Evidence Findings from clinical trials have demonstrated that gliptins are associated with significant vasoprotective effects with improvements in endothelial function (Table 4). 25,26,[36][37][38][39][40] Sitagliptin add-on therapy was evaluated in one controlled clinical trial of patients with uncontrolled T2DM despite already receiving antihyperglycemic medications. 25 The control group consisted of matched patients who received aggressive conventional therapy.…”